Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Albireo Pharma, Inc. (NASDAQ: ALBO).

Full DD Report for ALBO

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALBO)

Albireo to Present at the H.C. Wainwright Global Investment Conference
BOSTON, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, is scheduled to present at the H.C. Wain...
Source: GlobeNewswire
Date: August, 29 2018 08:30
Albireo Pharma (ALBO) Presents At 2018 Wedbush PacGrow Healthcare Conference - Slideshow
The following slide deck was published by Albireo Pharma, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: August, 15 2018 13:37
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2018 Results - Earnings Call Transcript
Albireo Pharma, Inc. (ALBO) Q2 2018 Earnings Conference Call August 7, 2018 8:30 a.m. ET Executives Paul Arndt - IR, LifeSci Advisors Ron Cooper - President and CEO Tom Shea - CFO Jan Mattsson - COO and Co-Founder Analysts Eun Yang - Jefferies Katherine Xu - William Bla...
Source: SeekingAlpha
Date: August, 07 2018 11:38
Albireo Pharma misses by $0.27, beats on revenue
Albireo Pharma (NASDAQ: ALBO ): Q2 EPS of -$1.22 misses by $0.27 . More news on: Albireo Pharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 07 2018 07:36
Albireo Reports Second Quarter 2018 Financial Results
A4250 Phase 3 trial in PFIC underway A4250 granted rare pediatric disease designation, eligible to apply for priority review voucher Management to host conference call and webcast today at 8:30 a.m. EDT BOSTON, Aug. 07, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO...
Source: GlobeNewswire
Date: August, 07 2018 07:30
Albireo to Report Second Quarter 2018 Financial Results, and Host Conference Call and Webcast on August 7, 2018
BOSTON, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that its second quarter financial results will be reported on August 7 prior to open of U.S. financia...
Source: GlobeNewswire
Date: August, 02 2018 16:01
Factors of Influence in 2018, Key Indicators and Opportunity within Finisar, Albireo Pharma, Corporate Office Properties Trust, Ocean Power Technologies, Depomed, and Potbelly - New Research Emphasizes Economic Growth
NEW YORK, July 31, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Finisar Corporation (NASDAQ:FNSR), Albireo Pharma, Inc. (NASDAQ:ALBO), Co...
Source: GlobeNewswire
Date: July, 31 2018 07:45
Albireo And A4250: The Pediatric Remedy Making Waves
Investment Thesis A4250, the lead drug candidate and an FDA rare pediatric disease designate from Albireo Pharma, is an investigative inhibitor of Ilea bile acid transporter (IBAT) that is being evaluated clinically for therapeutic efficacy in the pediatric cholestatic liver ...
Source: SeekingAlpha
Date: July, 30 2018 07:33
Albireo Appoints Patrick Horn MD, PhD as Chief Medical Officer
--- Pediatrician with extensive orphan drug development expertise --- --- Experience with multiple Phase 3 programs and FDA submissions --- BOSTON, July 25, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developi...
Source: GlobeNewswire
Date: July, 25 2018 08:30
Albireo Added to Russell 2000® Index
BOSTON, June 25, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that it has been added to the Russell 2000 ® Index as part of the annual reconstitution of the R...
Source: GlobeNewswire
Date: June, 25 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0833.6133.1334.0032.8732,826
2018-05-1733.8032.8233.9031.8668,846

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-112,9594,74562.3604Short
2018-12-1016,71376,33221.8951Cover
2018-12-078,52714,31859.5544Short
2018-12-061,0663,67129.0384Cover
2018-12-045,4297,01777.3692Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALBO.


About Albireo Pharma, Inc. (NASDAQ: ALBO)

Logo for Albireo Pharma, Inc. (NASDAQ: ALBO)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $367,026,954 - 05/14/2018
  • Issue and Outstanding: 11,897,146 - 03/01/2018

 


Recent Filings from (NASDAQ: ALBO)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 24 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 24 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 05 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 27 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: March, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 15 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 09 2018

 

 


Daily Technical Chart for (NASDAQ: ALBO)

Daily Technical Chart for (NASDAQ: ALBO)


Stay tuned for daily updates and more on (NASDAQ: ALBO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ALBO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALBO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ALBO and does not buy, sell, or trade any shares of ALBO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/